DIH Holding US’s (DHAI) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of DIH Holding US (NASDAQ:DHAI) in a report issued on Thursday morning,Weiss Ratings reports.

Separately, Wall Street Zen upgraded DIH Holding US to a “sell” rating in a report on Saturday, October 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, DIH Holding US has a consensus rating of “Sell”.

DIH Holding US Stock Performance

Shares of NASDAQ:DHAI opened at $1.84 on Thursday. The business’s 50 day simple moving average is $4.70 and its two-hundred day simple moving average is $5.39. The firm has a market cap of $3.85 million, a P/E ratio of -0.29 and a beta of 0.02. DIH Holding US has a 52-week low of $1.78 and a 52-week high of $73.25.

DIH Holding US (NASDAQ:DHAI) last announced its quarterly earnings results on Monday, October 20th. The company reported ($1.44) earnings per share (EPS) for the quarter. The business had revenue of $12.65 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DIH Holding US stock. Armistice Capital LLC purchased a new stake in shares of DIH Holding US, Inc. (NASDAQ:DHAI) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,078,000 shares of the company’s stock, valued at approximately $481,000. Armistice Capital LLC owned about 4.39% of DIH Holding US at the end of the most recent quarter. 27.76% of the stock is currently owned by institutional investors and hedge funds.

About DIH Holding US

DIH Holding US, Inc operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement.